ACTRN12614001114639Recruiting未知
Clinical utility of F18-ethyl-L-thyrosine (F18-FET) Positron Emission Tomography (PET) imaging, pre and post-radiotherapy, to assess prognosis and treatment response in high-grade glioma.
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Enrollment
- 60
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Non-randomised trial
- Primary Purpose
- Diagnosis
Eligibility Criteria
- Ages
- 18 Years to o limit (—)
- Sex
- All
Inclusion Criteria
- •Patients with newly diagnosed, histologically confirmed glioblastoma grade IV.
- •Planned to undergo radiotherapy or combined chemoradiotherapy
- •ECOG performance status 0-2
- •Able to undertake PET imaging
- •Able to provide written informed consent
Exclusion Criteria
- •Age < 18 yrs
- •Medical contraindication to PET imaging
- •Cognitive impairment resulting in inability to provide informed consent.
Investigators
Similar Trials
Completed
Phase 2
Study of Clinical Usefulness of 18F-fluorothymidine(FLT) PET/CT in Ditection of Peritoneal Metastases of Gastric CancerJPRN-UMIN000009329Department of Gastrointestinal Oncology, National Cancer Center Hospital in Japan40
Recruiting
Phase 2
FET PET in Differentiating Tumour Progression From Pseudoprogression in High Grade GliomaGlioma, MalignantNCT06172595Singapore General Hospital22
Recruiting
Not Applicable
Clinical study to evaluate the usefulness of 18F-FBPA-PET for patient selection and expanding indication for BNCTHead and Neck Cancer,Malignant gliomaJPRN-UMIN000035976Southern TOHOKU BNCT Research Center20
Recruiting
Not Applicable
Molecular Pituitary Imaging Using 18F-FET PETPituitary AdenomaNCT06584123University of Cambridge20
Completed
Not Applicable
Evaluation of 3'-deoxy-3'-[18F]fluorothymidine -PET and diffusion weighted imaging -MRI in patients with early stage non-small cell lung cancer treated with a platinum-based doublet as preoperative chemotherapy.Lungcancer10038666non-small cell lung cancerNL-OMON42040European Organisation for Research in Treatment of Cancer (EORTC)4